Skip to main content

Advertisement

Table 5 Clinical outcome

From: Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses

Groups a 0 1 2 3 4 5 6 Total
  EcoVag® Lc4R5 Lc23B33 Lc21M49 Lg14869, Lg14869 LaciBios®  
  Lg 14869 Lg 20M39 Lg 6M9 Lg 6M9 Lr 14870, Lr 14870 Lr GR-1  
  Lr 14870 Lj 22B42 Lj 12B1 Lc 8R6 Lg 15527 Lg 15527 Lr RC-14  
  Vaginal Vaginal Vaginal Vaginal Vaginal Oral Oral  
  n = 9 n = 12 n = 10 n = 10 n = 9 n = 4 n = 9 n = 63
6-month cure (no. and percentage) 8 (89%) 9 (75%) 8 (80%) 6 (60%) 6 (67%) 2 (50%) 8 (89%) 47 (74.6%)
12-month cure (no. and percentage) 7 (78%) 7 (58%) 6 (60%) 7 (70%) 6 (67%) 2 (50%) 6 (67%) 41 (65.1%)
24-month cure (no. and percentage) 5 (56%) 4 (33%) 6 (60%) 6 (60%) 6 (67%) 2 (50%) 6 (67%) 35 (55.6%)
Number of patients with new relation during follow up (no. and percentage of all) 2 (22%) 4 (33%) 4 (40%) 4 (40%) 2 (22%) 3 (75%) 3 (33%) 22 (34.9%)
  1. a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii